MOESM1 of Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Additional file 1: Table S1. History of IFN-α treatment in human B cell malignancies. Abbreviations: IFN, interferon; ND, newly diagnosed; RR, relapsed and/or refractory; MCL, mantel cell lymphoma; SLL, small lymphocytic lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B cell lymphoma; NHL, non-Hodgkin lymphoma; MALT, mucosa-associated lymphoid tissue; HL, Hodgkin lymphoma; pcMZL, primary cutaneous marginal zone lymphoma; CLL, chronic lymphocytic lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PTCL, peripheral T cell lymphoma; DLCL, diffuse large cell lymphoma; MM, multiple myeloma; WM, Waldenstrom’s macroglobulinemia; NK, natural killer; LG, large granular; IL, interleukin; HDT, high dose treatment; ASCT, autologous stem cell transplant; ABSCT, autologous bone marrow or blood stem cell transplantation; PBSCT, peripheral blood stem cell transplantation; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisone; UA, unavailable; *IFN Dose: high-dose IFN (5 MIU/m2 daily), low-dose (3 MIU/m2/day, 3 times a week), intermediate-dose, between high and low doses.